Journal of Pharmaceutical Practice 2023;41(6):352-357

doi:10.12206/j.issn.2097-2024.202112019

Research progress on drug combination therapy against Candida albicans

Zhongyu DENG 1 ; Shijin GUO 1 ; Yifan GUO 1 ; Juncheng FENG 1 ; Quanzhen LYU 2 ; Lijuan QIU 1

Affiliations

+expand

Keywords

Candida albicans; combination therapy; azole; polyenes; echinocandins; photodynamic therapy; ultrasonic therapy; silver nanoparticles

Country

China

Language

Chinese

Abstract

Candida albicans is one of the most common species of Candida, which is an important cause of invasive candidiasis in clinic. Due to the frequently use of classical antifungal agents, there are amounts of drug resistant C. albicans being isolated, causing the significantly decreasing of the efficacy of some antifungal agents in clinical treatment. Besides, the use of some compounds in clinic has been limited because of their toxicities. In such a context, drug combination therapy shows great potential on antifungal because of the synergy of different drugs or therapeutic methods that could bring, which could improve the weaknesses of single drug.